SecBot SecBot
PRESS-RELEASE ·Filed Aug 28, 2026
RN

RNAQU

Rainier Acquisition Corporation
NEUTRAL
Impact 4/10
Horizonmonths Processed1mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for target announcement and shareholder vote — SPAC must complete a business combination within ~24 months or liquidate. The life sciences focus may attract biotech targets. Track trust value per share and redemption trends post-announcement.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+20d
RNAQU ▲ +0.04% at T+20d
NEUTRAL call +0.04% · α vs SPY -0.22% · entry $10.18 → $10.18
Next anchor: T+60d in 27d
Entry = T+0 close
Aug 28, 2026
via day close
T+1d
+0.05%
call +0.05% · α +0.35%
$10.18
settled 8w ago
T+5d
+0.25%
call +0.25% · α +0.14%
$10.20
settled 8w ago
T+20d
+0.04%
call +0.04% · α -0.22%
$10.18
settled 29d ago
T+60d
Pending
in 27d

Price Chart

Loading chart...

Executive Summary

Rainier Acquisition Corporation (RNAQU) closed its $75M IPO of 7.5M units at $10.00/unit, each consisting of one Class A ordinary share and one-quarter of a redeemable warrant. The SPAC will focus on life sciences targets. Proceeds are held in trust pending a business combination, with no operating revenue or earnings to evaluate. This is a routine SPAC IPO — the event is neutral for the trust value but carries the standard risk of no deal within 24 months.

Key Financial Metrics

Deal Value
$75.0M

Key Facts

  • Closed IPO of 7,500,000 units at $10.00/unit, gross proceeds $75,000,000
  • Each unit: one Class A ordinary share + one-quarter redeemable warrant (exercise price $11.50/share)
  • Units trade on Nasdaq under RNAQU; shares and warrants expected to list separately under RNAQ and RNAQW
  • SPAC targeting global life sciences (therapeutics, diagnostics, genomics, precision medicine, biomanufacturing)
  • Management: CEO Gbola Amusa (MD, CFA), CFO Guy Barudin; Chardan sole book-runner
  • Underwriter has 45-day option for up to 1,125,000 additional units at IPO price

Financial Impact

Gross proceeds of $75,000,000 from IPO, before underwriting discounts and expenses. No operating revenue or earnings.

cashdilution

Risk Factors

  • No identified target yet — risk of no deal and liquidation
  • Warrant dilution if exercised (11.50 strike, 7.5M shares from initial warrants)
  • Underwriter over-allotment could add up to 1.125M more units (additional $11.25M)
  • SPAC market conditions may affect ability to find and close a target

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3352871
3 reports for RNAQU
Performance horizon
Filters
Rows
Reports for RNAQU — sortable, filterable
TypeNow
Sep 2, 2026
7w ago
Press Release
NEUTRAL ★ 3/10
$10.18 $10.07▼ −1.13%▼ −0.98%$10.03 (−1.47%)
Aug 28, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$10.18 $10.18▲ +0.04%▼ −0.22%$10.03 (−1.43%)
Aug 26, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$10.16 $10.17▲ +0.10%▲ +0.61%$10.03 (−1.28%)
Showing 3 of 3

US Market Status

Market Open — Closes in 4h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026